Dexcom director reports 42 shares via trust

Q: How many DXCM shares does Glenn S. Boehnlein report owning in this Form 3?

He reports beneficial ownership of 42 shares of Dexcom common stock, as of the reporting date in the Form 3.

Q: Are Glenn S. Boehnlein’s DXCM shares held directly or indirectly?

They are held indirectly through the Boehnlein 2017 Trust, with Glenn S. Boehnlein and his spouse serving as co-trustees of that trust.

Q: What is the role of the Boehnlein 2017 Trust in this DXCM Form 3?

The Boehnlein 2017 Trust is the entity that holds the 42 Dexcom common shares. Glenn S. Boehnlein and his spouse act as co-trustees of this trust, which results in his reported beneficial ownership.

Q: Does this DXCM Form 3 report any recent stock transactions by Glenn S. Boehnlein?

No. The Form 3 reports existing beneficial ownership of 42 Dexcom common shares held via a trust and does not list any purchase, sale, or derivative transactions.

Dexcom director Glenn S. Boehnlein reports indirect ownership of 42 common shares held through a family trust.

Available on EDGAR 09/10/2026 - 04:37 PM EDT Accepted by SEC EDGAR 09/10/2026 - 04:36 PM EDT

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

DEXCOM INC (DXCM) reports that director Glenn S. Boehnlein has filed an initial statement of beneficial ownership of securities. The filing shows 42 shares of common stock held indirectly through the Boehnlein 2017 Trust, for which he and his spouse serve as co-trustees. No purchase, sale, or derivative transactions are reported.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider Boehnlein Glenn S

Role Director

Type	Security	Shares	Price	Value
Holding	Common Stock ^F1	--	--	--

Holdings: Common Stock — 42 shares (Indirect, By Trust)

Footnotes (1)

F1. Shares are held by the Boehnlein 2017 Trust, with respect to which the Reporting Person and the Reporting Person's spouse are co-trustees.

Key Figures

Common stock indirectly held: 42 shares Reporting persons: 1 Indirect holding entities: 1 trust

3 metrics

Common stock indirectly held 42 shares Beneficial ownership of Dexcom common stock reported by director Glenn S. Boehnlein

Reporting persons 1 Single reporting person, Glenn S. Boehnlein, identified as a director

Indirect holding entities 1 trust Shares held through the Boehnlein 2017 Trust, with the director and spouse as co-trustees

Key Terms

co-trustees, Trust

2 terms

co-trustees other

"with respect to which the Reporting Person and the Reporting Person's spouse are co-trustees"

Trust financial

"Shares are held by the Boehnlein 2017 Trust, with respect to which the Reporting Person"

A trust is a legal setup in which one party (the trustee) holds and manages assets—like cash, stocks or property—on behalf of other people (beneficiaries) according to instructions from the person who created it (the grantor). Think of it as a locked box with a keyholder who must follow written rules; for investors it matters because trusts influence who controls and benefits from assets, affect taxes and succession, and can change how quickly or transparently shares are bought, sold or voted.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does this Form 3 filing for DXCM disclose about Glenn S. Boehnlein?

It discloses that Glenn S. Boehnlein, a director of Dexcom, has beneficial ownership of 42 shares of Dexcom common stock, held indirectly through the Boehnlein 2017 Trust where he and his spouse are co-trustees.

How many DXCM shares does Glenn S. Boehnlein report owning in this Form 3?

He reports beneficial ownership of 42 shares of Dexcom common stock, as of the reporting date in the Form 3.

Are Glenn S. Boehnlein’s DXCM shares held directly or indirectly?

They are held indirectly through the Boehnlein 2017 Trust, with Glenn S. Boehnlein and his spouse serving as co-trustees of that trust.

What is the role of the Boehnlein 2017 Trust in this DXCM Form 3?

The Boehnlein 2017 Trust is the entity that holds the 42 Dexcom common shares. Glenn S. Boehnlein and his spouse act as co-trustees of this trust, which results in his reported beneficial ownership.

Does this DXCM Form 3 report any recent stock transactions by Glenn S. Boehnlein?

No. The Form 3 reports existing beneficial ownership of 42 Dexcom common shares held via a trust and does not list any purchase, sale, or derivative transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Boehnlein Glenn S

(Last)

(First)

(Middle)

6340 SEQUENCE DRIVE

(Street)

SAN DIEGO

CALIFORNIA

92121

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
09/10/2026

3. Issuer Name and Ticker or Trading Symbol
DEXCOM INC [ DXCM ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	42	I	By Trust⁽¹⁾

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)

Explanation of Responses:

1. Shares are held by the Boehnlein 2017 Trust, with respect to which the Reporting Person and the Reporting Person's spouse are co-trustees.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Jereme M. Sylvain, as Attorney-in-Fact for Glenn S. Boehnlein	09/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR